Hepatitis B immunoglobulins of 4 different manufacturers were administered intramuscularly into 37 healthy adults. Each person received an amount of 0.1 ml per kg bodyweight. Blood samples were taken on days 3, 7, 14, 21, 28, 63, 98 and 126 after passive immunization. The anti-HBs serum levels were determined using the International Reference Preparation of anti-HBs as standard reagent. The highest serum levels were seen on day 3 (38.9% of the test persons), day 7 (41.7%), day 14 (11.1%), and day 21 (8.3%) after application of the immunoglobulins with mean values between 138 and 355 mU anti-HBs/ml. The half-life of the preparations in man showed mean values between 17.5 and 25 days. The shortest half-life was 5.9 and the longest 35 days. Four months after passive immunization the anti-HBs levels had decreased to a percentage of 1.2 to 2.5 of the maximum serum concentration (1.7 to 8.9 mU anti-HBs/ml). The passive immunization via the intramuscular route does not accomplish an instantaneously available, maximum anti-HBs titer. There seems to be a great range of variation in uptake and elimination of the immunoglobulins in man. Still, since preparations for intravenous application are not at hand, hepatitis B immunoglobulins for intramuscular use must play a major role in post-exposure prophylaxis of hepatitis B virus infection.
Download full-text PDF |
Source |
---|
Gynecol Obstet Invest
January 2025
Objectives: To evaluate the impact of a comprehensive intervention using nursing-sensitive quality indicators on pregnant women with hepatitis B and their newborns.
Design: A randomized controlled monocentric trial conducted from January 2020 to May 2022. Participants/Materials: 80 pregnant women diagnosed with hepatitis B were randomly assigned to either a control group (n=40) or an experimental group (n=40).
Hum Vaccin Immunother
December 2025
School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.
ClinicalTrials.gov (NCT03962816).https://clinicaltrials.
View Article and Find Full Text PDFNeurology
February 2025
Department of Preventive Medicine and Epidemiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.
Background And Objectives: Hepatitis B vaccination (HBV) requires 6 months to complete and is recommended for patients with multiple sclerosis (PWMS), particularly those who are candidates for anti-CD20 therapy. However, limited data exist on HBV immunogenicity in PWMS receiving disease-modifying therapies (DMTs) and the impact of starting anti-CD20 therapy during immunization. We aimed to evaluate HBV immunogenicity in PWMS starting anti-CD20 therapy during vaccination, focusing on the number of doses received before anti-CD20 initiation.
View Article and Find Full Text PDFImmunity
January 2025
Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; St Vincent's Clinical School, UNSW Sydney, Sydney, NSW, Australia. Electronic address:
The unexplained association between infection and autoimmune disease is strongest for hepatitis C virus-induced cryoglobulinemic vasculitis (HCV-cryovas). To analyze its origins, we traced the evolution of pathogenic rheumatoid factor (RF) autoantibodies in four HCV-cryovas patients by deep single-cell multi-omic analysis, revealing three sources of B cell somatic mutation converged to drive the accumulation of a large disease-causing clone. A method for quantifying low-affinity binding revealed recurring antibody variable domain combinations created by V(D)J recombination that bound self-immunoglobulin G (IgG) but not viral E2 antigen.
View Article and Find Full Text PDFJ Clin Invest
January 2025
Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland.
Autoimmune hepatitis (AIH) is a rare chronic inflammatory liver disease characterized by the presence of autoantibodies, including those targeting O-phosphoseryl-tRNA:selenocysteine-tRNA synthase (SepSecS), also known as soluble liver antigen (SLA). Anti-SepSecS antibodies have been associated with a more severe phenotype, suggesting a key role for the SepSecS autoantigen in AIH. To analyze the immune response to SepSecS in patients with AIH at the clonal level, we combined sensitive high-throughput screening assays with the isolation of monoclonal antibodies (mAbs) and T cell clones.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!